Aventis Retains Revasc; Refludan Divestment Ordered By FTC
Executive Summary
Aventis' Refludan is available for licensing through the New York City investment banking company Ferghana Partners as a result of an Aug. 25 Federal Trade Commission order.
You may also be interested in...
Specialty Pharma Canyon Takes Leech-Inspired Anticoagulant Approved In 2003 To Market
Iprivask, "the first direct thrombin inhibitor approved in the U.S.," was found superior to both heparin and Lovenox but fell through the cracks during pharma M&A activity, Canyon exec says.
Schering AG agrees to license Refludan
The Federal Trade Commission is accepting comments until Sept. 12 on a proposal by Aventis to divest the direct thrombin inhibitor Refludan (lepirudin) to Schering AG. Aventis was ordered to divest Refludan after failing to complete a divestment of the pending Revasc (desirudin), as required under the FTC consent agreement allowing the merger of Hoechst and Rhone-Poulenc (1"The Pink Sheet" Sept. 4, 2000, p. 17)
Schering AG agrees to license Refludan
The Federal Trade Commission is accepting comments until Sept. 12 on a proposal by Aventis to divest the direct thrombin inhibitor Refludan (lepirudin) to Schering AG. Aventis was ordered to divest Refludan after failing to complete a divestment of the pending Revasc (desirudin), as required under the FTC consent agreement allowing the merger of Hoechst and Rhone-Poulenc (1"The Pink Sheet" Sept. 4, 2000, p. 17)